albumin-bound paclitaxel
ApprovedSmall molecule
Bristol-Myers Squibbalbumin-bound paclitaxel is one of 475 small molecule programs targeting Esophageal Squamous Cell Carcinoma. It is currently in Approved.
20
Indications
71
Total Trials
38
Active Trials
474
Competitors
Pipeline
Status by Indication[3][1]
Indication
Showing 10 of 20 indications
Competition
Competitive Landscape
2828 competitors in Breast Cancer
#DrugCompanyPhaseTrials
1albumin-bound paclitaxel
Bristol-Myers SquibbApproved
Tecentriq
RochePreclinical
Halaven
EisaiPreclinical
DATROWAY
Daiichi SankyoPreclinical
MS Contin
Merck & Co.Preclinical
Zolymbus
AbbViePreclinical
Methylthioninium Chloride
PProvepharm SAS
Preclinical
MS Contin
HHikma Pharmaceuticals LLC
Preclinical
Effexor
WWyeth-Lederle Vaccines
Preclinical
Recentin
NNational Cancer Institute (NCI)
Preclinical
Ranked by pipeline maturity and clinical activity. Current drug highlighted in teal.
Timeline
Expected Milestones
Q4 2026
Phase 2Not yet recruiting
Second-Line Treatment
NCT06028633
Phase 2Not yet recruiting
Neoadjuvant Chemoimmunotherapy
NCT07346807
Phase 1/2Active, not recruiting
Advanced or Metastatic Solid Tumors
NCT04396821
Phase 1/2Recruiting
Esophageal Cancer
NCT04278287
Post-ApprovalRecruiting
Pancreatic Cancer
NCT05035147
Clinical
Trials by Indication[1]
Breast Cancer12 trials
Show 9 more trials
Gastric Cancer5 trials
Show 2 more trials
Safety and Efficacy of Systemic Chemotherapy Plus PD-1 Inhibitor in Combination With Bevacizumab in Gastric Cancer With Peritoneal Metastasis
Enrolling by invitation·UUnion Hospital, Tongji Medical College, Huazhong University of Science and Technology·Phase 2·NCT06487715·42 enrolled
Pancreatic Cancer5 trials
Albumin-bound Paclitaxel Combined With Gemcitabine First-line Inoperable Pancreatic Cancer
Recruiting·TTianjin Medical University Cancer Institute and Hospital·Phase 4·NCT05035147·934 enrolled
Esophageal Squamous Cell Carcinoma4 trials
33 more indications
Esophageal Cancer3 trials
Chemoradiotherapy in Unresectable Esophageal Cancer
Recruiting·—·Phase 1/2·NCT04278287·105 enrolled
Study of PD-1 Antibody Combined With Chemoradiotherapy in Oligometastatic Esophageal Cancer
Completed·—·Phase 2·NCT04821765·35 enrolled
Adenocarcinoma2 trials
Nasopharyngeal Carcinoma2 trials
Paclitaxel (Albumin-bound) Combined With Radiotherapy for the Treatment of Early Stage Nasopharyngeal Carcinoma
Unknown status·TThe Affiliated Nanjing Drum Tower Hospital of Nanjing University Medical School·Phase 3·NCT04766359·364 enrolled
Second-line Treatment2 trials
Cervical Cancer2 trials
Patients With Advanced Solid Tumors2 trials
Non-Small Cell Lung Cancer2 trials
Advanced/Metastatic Solid Tumors2 trials
CD73/AXL Targeted HypoSti.CAR-T Cells in CD73/AXL Positive Advanced/Metastatic Solid Tumors
Not yet recruiting·—·Phase 1/2·NCT06939270·30 enrolled
Pan-T Booster Co-expressing MSLN CAR T Cell Therapy in Advanced/Metastatic Solid Tumors
Recruiting·—·Phase 1/2·NCT05693844·15 enrolled
Head and Neck1 trial
Neoadjuvant Chemotherapy1 trial
Effect of Albumin-bound Paclitaxel Plus Carboplatin Compared With Paclitaxel Plus Carboplatin in Patients Receiving Neoadjuvant Chemotherapy for Advanced Ovarian, Fallopian Tube or Peritoneal Cancer: A Phase 2 Single Center Clinical Trial
Unknown status·SSun Yat-Sen Memorial Hospital of Sun Yat-Sen University·Phase 2·NCT05316376·78 enrolled
Paclitaxel1 trial
Head and Neck Squamous Cell Carcinoma1 trial
Neoadjuvant Toripalimab + Chemotherapy ± Cetuximab in Locally Advanced Head and Neck Squamous Cell Carcinoma (Neo-ICT)
Not yet recruiting·SShanghai Ninth People's Hospital Affiliated to Shanghai Jiao Tong University·Phase 3·NCT06647563·355 enrolled
Neoadjuvant Chemoimmunotherapy1 trial
Advanced or Metastatic Solid Tumors1 trial
Lung Cancer1 trial
Oropharyngeal Cancer1 trial
Neoadjuvant Tislelizumab Plus Chemotherapy for Locally Advanced Oral/Oropharyngeal Cancer (NeoSPOT)
Active, not recruiting·—·Phase 2·NCT06009861·110 enrolled
Immunotherapy1 trial
Intra-arterial Chemotherapy Combined with Radiotherapy and Immunotherapy for HNSCC
Recruiting·—·Phase 2·NCT06725498·50 enrolled
First-line Treatment1 trial
Albumin-Bound Paclitaxel Combined With Antiangiogenic Agents in First-line Treatment of Relapsed or Metastatic TNBC
Recruiting·TThe First Affiliated Hospital of Bengbu Medical University·Phase 2·NCT05192798·128 enrolled
Penile Cancer1 trial
Nab-paclitaxel1 trial
Clinical Study of Nab-paclitaxel Combined With Toripalimab in Local Advanced or Metastatic G/GEJ Carcinoma
Unknown status·—·N/A·NCT04443036·44 enrolled
Urothelial Carcinoma1 trial
Pancreatic Ductal Adenocarcinoma1 trial
Neoadjuvant Treatment1 trial
Cutaneous Melanoma1 trial
Ovarian Cancer1 trial
Soft Tissue Sarcoma1 trial
Neoadjuvant Therapy1 trial
Neoadjuvant Therapy of Sintilimab Combined With Chemotherapy for Resectable Squamous Cell NSCLC（neoSCORE Ⅱ）
Recruiting·SSecond Affiliated Hospital, School of Medicine, Zhejiang University·Phase 3·NCT05429463·250 enrolled
Esophageal Squamous Carcinoma1 trial
Tislelizumab Combined With Chemotherapy for the Perioperative Treatment of Esophageal Squamous Carcinoma
Not yet recruiting·TThe First Affiliated Hospital of Xiamen University·Phase 2·NCT07019181·26 enrolled
Resectable NSCLC1 trial
Neoadjuvant of Sintilimab Combined With Chemotherapy for Resectable NSCLC（neoSCORE）
Unknown status·SSecond Affiliated Hospital, School of Medicine, Zhejiang University·Phase 2·NCT04459611·60 enrolled
Sources
References
- [1]
- [2]
- [3]Open Targets Platform — Drug–disease associations for albumin-bound paclitaxel. EMBL-EBI & Wellcome Sanger Institute.
- [4]
Details
Drug Info
Quick Facts
- Modality
- Small molecule[2]
- Highest Phase
- Approved[1]
- Company